UCBG 2-04: Long-term results of the PACS 04 trial evaluating adjuvant epirubicin plus docetaxel in node-positive breast cancer and trastuzumab in the human epidermal growth factor receptor 2–positive subgroup

Auteurs

Véronique D'Hondt, Jean-Luc Canon, Lise Roca, Christelle Levy, Jean-Yves Pierga, Fanny Le Du, Mario Campone, Isabelle Desmoulins, Anthony Goncalves, Marc Debled, Maria Rios, Jean-Marc Ferrero, Daniel Serin, Anne-Claire Hardy-Bessard, Gilles Piot, Etienne Brain, Nadine Dohollou, Hubert Orfeuvre, Jerome Lemonnier, Henri Roché, Suzette Delaloge, Florence Dalenc